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Abstract
T cell immunoglobulin and mucin domain-containing protein 3 (Tim-3) is a newly identified negative immunomodulator
that is up-regulated on dysfunctional T cells during viral infections. The expression and function of Tim-3 on human innate
immune responses during HCV infection, however, remains poorly characterized. In this study, we report that Tim-3 is
constitutively expressed on human resting CD14
+ monocyte/macrophages (M/MØ) and functions as a cap to block IL-12, a
key pro-inflammatory cytokine linking innate and adaptive immune responses. Tim-3 expression is significantly reduced and
IL-12 expression increased upon stimulation with Toll-like receptor 4 (TLR4) ligand - lipopolysaccharide (LPS) and TLR7/8
ligand - R848. Notably, Tim-3 is over-expressed on un-stimulated as well as TLR-stimulated M/MØ, which is inversely
associated with the diminished IL-12 expression in chronically HCV-infected individuals when compared to healthy subjects.
Up-regulation of Tim-3 and inhibition of IL-12 are also observed in M/MØ incubated with HCV-expressing hepatocytes, as
well as in primary M/MØ or monocytic THP-1 cells incubated with HCV core protein, an effect that mimics the function of
complement C1q and is reversible by blocking the HCV core/gC1qR interaction. Importantly, blockade of Tim-3 signaling
significantly rescues HCV-mediated inhibition of IL-12, which is primarily expressed by Tim-3 negative M/MØ. Tim-3 blockade
reduces HCV core-mediated expression of the negative immunoregulators PD-1 and SOCS-1 and increases STAT-1
phosphorylation. Conversely, blocking PD-1 or silencing SOCS-1 gene expression also decreases Tim-3 expression and
enhances IL-12 secretion and STAT-1 phosphorylation. These findings suggest that Tim-3 plays a crucial role in negative
regulation of innate immune responses, through crosstalk with PD-1 and SOCS-1 and limiting STAT-1 phosphorylation, and
may be a novel target for immunotherapy to HCV infection.
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Introduction
HCV is a serious and growing threat to public health, affecting
approximately 4 million U.S. citizens and 200 million people
worldwide [1]. The most remarkable feature of this blood-borne
virus is its ability to evade host immunity, resulting in over 80% of
infected individuals developing chronic infection that is associated
with liver cirrhosis and hepatocellular carcinoma – thus becoming
a leading cause for liver transplantation [1]. Unfortunately, the
current standard treatment with pegylated interferon and ribavirin
(IFN/RBV) has limited effectiveness (less than 50% respond) for
the most prevalent viral genotypes (1a/1b) in the U.S [1]. No
vaccine is currently available, in part due to our incomplete
understanding of HCV-host interactions that lead to viral
persistence.
Tim-3 is a type 1 membrane protein with a structurally
conserved immunoglobulin variable (IgV) domain and mucin stalk
that connects to an intracellular tail [2]. Tim-3 was initially
identified expressed on activated Th1 cells, rather than Th2 cells,
and the interaction between Tim-3 and its ligand, galectin-9 (gal-
9), was shown to inhibit Th1 responses and induce cell death in
individuals with autoimmune disorders [3–6]. Recently, Tim-3 has
been found to be over-expressed on T cells in chronic viral
infections, and its blockade rescued the exhausted virus- specific
CD4
+ and CD8
+ T cell functions [7–10]; meanwhile, kupffer cell-
derived galectin-9 (gal-9, Tim-3 ligand) has also been shown to
play a role in regulation of T cell immunity in HCV infection [11].
Thus, the Tim-3/gal-9 pathway appears to function as negative
signaling and play an important role in T cell dysfunction during
chronic viral infections.
In addition to T cells, Tim-3 expression has recently been
shown on innate immune cells, notably antigen presenting cells
(APCs), and has more complex functions in immune dysregulation
[12–15]. While extensive studies have shown Tim-3 as an
inhibitory molecule on Th1/Tc1 cells, its role in M/MØ as well
as maturation and function of dendritic cells (DC) is rather
controversial. On the one hand, Tim-3 has been shown to
negatively regulate macrophage activation, and Tim-3 signaling
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adaptive immune responses [12–13]. On the other hand, Tim-3 and
gal-9 has been reported to induce maturation of human monocyte-
derived DC (MDDC) and promote phagocytosis of apoptotic cells
and cross-presentation of dying cell-associated antigen to T cells [14–
16]. The expression and function of Tim-3, and its relationship with
other negative immunoregulators such as programmed death-1 (PD-
1) and suppressor of cytokine-1 (SOCS-1), in innate immune
regulation during HCV infection remain unknown. In this report,
weassessedtheexpressionandeffectofTim-3onhumanM/MØand
IL-12 regulation during chronic HCV infection. We found that Tim-
3i so v e r - e x p r e s s e do nb o t hu n - s t i m u l a t e da n dT L R - s t i m u l a t e dM /
MØ and is negatively associated with the impaired IL-12 production
in chronically HCV-infected individuals when compared to healthy
subjects. HCV (core) increases Tim-3 expression and inhibits IL-12
production in primary M/MØ or monocytic THP-1 cells, an effect
that mimics C1q and is reversibleby blocking the HCV core/gC1qR
interaction. Importantly, blockade of Tim-3 signaling significantly
improves the HCV-mediated suppression of IL-12, which is primarily
expressed by Tim-3 negative M/MØ. We also found that Tim-3
alters the expressions of PD-1 and SOCS-1 to coordinately inhibit
M/MØIL-12production bylimiting theSTAT-1 phosphorylation in
M/MØ. These findings suggest that Tim-3 is able to cooperative with
other inhibitory molecules and plays a crucial role in negative
regulation of innate immune responses during chronic viral infection.
Results
Tim-3 is over-expressed on resting and activated CD14
+
M/MØ and is associated with diminished IL-12 expression
in chronic HCV infection
Tim-3 has been shown to be over-expressed on and involved in
inhibiting viral specific T cell responses during HCV infection [9].
The expression and role of Tim-3 in regulation of M/MØ function
during HCV infection remains undefined. To address this, Tim-3
expression, along with intracellular IL-12 production, in resting
and TLR-stimulated M/MØ of chronically HCV-infected patients
and healthy subjects, were examined by flow cytometry. As shown
in the representative dot plots, time-course, and summary data of
Tim-3 expression on CD14
+ M/MØ of healthy subjects (n=12,
multiple assays, p,0.001) and HCV-infected individuals (n=21,
p,0.001) in Fig. 1A through D, Tim-3 is constitutively expressed
on resting M/MØ; its expression significantly decreases upon cell
activation, as early as 6 h, after stimulation with Toll-like receptor
4 (TLR4) ligand - lipopolysaccharide (LPS) and TLR7/8 ligand -
R848, which can synergistically activate primary M/MØ to
produce IL-12 [17,18]. Notably, chronically HCV-infected
individual exhibits significantly elevated Tim-3 expression on
CD14
+ M/MØ, in both the un-stimulated and TLR-stimulated
states, when compared to healthy subjects. In contrast to the
elevated Tim-3 expression, IL-12 expression is barely detectable in
resting M/MØ; its expression is significantly increased in CD14
+
M/MØ following TLR stimulation, but to a lesser extent and
leading to an impaired IL-12 expression in the setting of chronic
HCV infection compared to healthy subjects.
To further determine whether Tim-3 expression correlates with
IL-12 production in M/MØ, we examined their expressions in all
participants by flow cytometry at single cell basis with triple
immunostaining and Pearson correlation analysis. As shown in the
representative dot plot and summary data in Fig. 2A and B, Tim-3
is highly expressed on un-stimulated ‘‘naı ¨ve’’ CD14
+ M/MØ,i n
peripheral blood of both healthy subjects and chronically HCV-
infected individuals, which produce negligible IL-12; once TLR-
stimulated, Tim-3 expression is diminished, which is very
significantly and inversely correlated to M/MØ IL-12 expression,
primarily by CD14
+Tim-3
2 M/MØ.
Tim-3 and IL-12 expressions are differentially regulated in
M/MØ co-cultured with hepatocytes expressing live HCV
The observed Tim-3 up-regulation on M/MØ during chronic
HCV infection might be a result rather than a cause of IL-12
suppression. To further elucidate the role of HCV in regulation of
Tim-3 and IL-12 expression and to more accurately mimic the in
vivo setting of chronic HCV infection, we employed a newly
established cell culture system by transfecting Huh-7 hepatocytes
with the HCV-JFH-1 strain in vitro [19,20] As shown in Fig. 3A,
HCV core as well as NS5 protein (Fig.S1A) is detected in HCV-
JFH-1-transfected Huh-7 hepatocytes, but not in mock-transfected
controls, by immunofluorescent staining. HCV core mRNA is also
detected by RT-PCR in the supernatant of the HCV-transfected
Huh-7 cells but not in the culture of controls (Fig.S1B).
Additionally, uninfected Huh-7 cells can be infected by the
supernatant of JFH-1-transfected Huh-7 cells (Fig.S1C), suggesting
that live HCV particles are secreted from the HCV mRNA-
transfected hepatocytes. We then incubated purified healthy M/
MØ with Huh-7 cells 48 h after HCV transfection, followed by
detection of Tim-3 and IL-12 expressions in M/MØ with or
without TLR stimulation for 18 h. As shown in Fig. 3B, Tim-3
expression is found to be up-regulated on purified M/MØ co-
cultured with hepatocytes expressing live HCV when compared
with HCV
2 hepatocytes, in both the un-stimulated and LPS/
R848-stimulated state. As described above, Tim-3 is expressed at
relatively high levels on M/MØ cultured with hepatocytes without
TLR stimulation (Fig. 3B, left panel) when compared to those with
LPS/R848 stimulation for 18 h (Fig. 3B, right panel); however, in
either scenario, Tim-3 is up-regulated by HCV exposure. To
determine the dynamics of Tim-3 up-regulation by HCV, we
kinetically examined Tim-3 expression on M/MØ at various time-
points after co-culture with HCV
+ Huh-7 versus HCV
2 Huh-7
without TLR stimulation. As shown in Fig. 3C, at all time-points
examined, the expression of Tim-3 on CD14
+ M/MØ incubated
with HCV-expressing Huh-7 cells is remarkably higher than those
co-cultured with HCV
2 hepatocytes. We also examined IL-12
expression in M/MØ incubated with HCV
+ hepatocytes or HCV
2
hepatocytes for 18 h, as shown in a Fig. 3D dot plot, histogram,
and bar figure derived from multiple repeated experiments, HCV
+
Huh-7 significantly inhibits IL-12 production by CD14
+ M/MØ.
HCV core protein up-regulates Tim-3 expression and
down-regulates IL-12 production in primary M/MØ and
THP-1 cells
Previous studies suggest that Tim-3, PD-1, and SOCS-1
pathways are involved in negative regulation of T and B
lymphocyte functions during HCV infection [10–11,21–28].
Additionally, PD-1 and SOCS-1 has been demonstrated to
negatively regulate IL-12 production in murine [29–32] as well
as in human M/MØ during HCV infection or by HCV core
treatment [33–34]. As such, we speculated that Tim-3 might also
be involved in negative regulation of M/MØ function following
exposure to HCV core protein. To examine this possibility,
healthy PBMC were stimulated with LPS/R848 in the presence of
HCV core or b-gal control for 18 h, and then subjected to analysis
of Tim-3 and IL-12 expressions by flow cytometry. Fig. 4A shows
the gating strategy in dot plots from a representative experiment
and summary data from 8 subjects for analysis of Tim-3 versus IL-
12 expressions in CD14
+ M/MØ with no stimulation, LPS/R848/
b-gal, and LPS/R848/core stimulation. Indeed, compared to b-
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and down-regulates IL-12 production in CD14
+ M/MØ.
Up-regulation of Tim-3 in PBMC treated with HCV core might
be secondary to stimulation by cytokines secreted from other
immune cell populations rather than by a direct antigenic effect on
M/MØ. To exclude this possibility, we also stimulated a human
monocytic cell line, THP-1, with LPS/R848 in the presence of
HCV core or b-gal for 48 h and 72 h, and then detected Tim-3
and IL-12 expressions by flow cytometry. As shown in Fig. 4B,
Tim-3 expression is significantly up-regulated, while IL-12
production is moderately down-regulated by HCV core treatment
at 48 h (data not shown); and this dysregulation by HCV core
protein is clearly observed at 72 h when compared to THP-1 cells
treated with b-gal control protein. These data is reproducible in
purified M/MØ treated with LPS and core for 18 h, in that i) Tim-
3 is highly expressed on resting M/MØ with little if any IL-12
production; ii) Tim-3 significantly declines upon TLR stimulation
that is accompanied by increased IL-12 expression; and iii) Tim-3
is moderately up-regulated along with IL-12 down-regulated by
HCV core protein (Fig. 4C). Taken together, these results suggest
that HCV core enhances Tim-3 expression on both primary
CD14
+ M/MØ and THP-1 cells, and inhibits IL-12 expression
that is primarily produced by Tim-3 negative M/MØ.
HCV core mimics C1q to regulate M/MØ functions
through interaction with gC1qR
We have previously demonstrated that HCV core protein
differentially regulates T and B lymphocytes and inhibits IL-12
production through interaction with a complement receptor,
gC1qR, expressed on these immune cells [23–28,33–41]. gC1qR
is an immunoreceptor initially identified by its ability to bind the
globular head of C1q – the first component of the C1 complex in
the complement system, which plays a crucial role in innate
immunity against microbial antigens circulating in the blood of the
infected host [42]. Engagement of C1q with gC1qR leads to
multiple cellular activities including immunosuppression [42]. To
Figure 1. Tim-3 is over-expressed and IL-12 expression suppressed on CD14
+ M/MØ in chronically HCV-infected individuals. PBMC
from chronically HCV-infected subjects (n=21) and healthy subjects (n=12) were stimulated with or without TLR ligands LPS and R848 for 18 h,
followed by immunostaining with antibodies against Tim-3, IL-12 and CD14. Tim-3 and IL-12 expressions in un-stimulated and LPS/R848-stimulated
CD14
+ M/MØ were examined by flow cytometry. A) Representative flow cytometric dot plots measuring Tim-3 expression and IL-12 production in
CD14
+ M/MØ. B) Time-course of Tim-3 expression in primary healthy M/MØ. PBMC stimulated with LPS and R848 for the indicated times. Tim-3
expression on CD14
+ M/MØ was assessed by flow cytometry; corresponding changes in % gated and MFI are shown with isotype control. C) Summary
data of the percentage of Tim-3
+ and D) IL-12
+ cells in CD14
+ M/MØ of healthy subjects and chronically HCV-infected individuals, in naı ¨ve and TLR-
activated state, are shown. Each symbol represents an individual subject, and the horizontal bars represent median values. The p value (**,0.01;
***,0.001) is denoted above the group of study subjects.
doi:10.1371/journal.pone.0019664.g001
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innate immune cells through interaction with gC1qR, we treated
THP-1 cells with gC1qR’s natural ligand, C1q (0, 50, and 100 mg/
ml), and LPS/R848 for 48,72 h, followed by examination of the
expressions of Tim-3 and IL-12 by flow cytometry. As shown in
Fig. 5A, Tim-3 is up-regulated, while IL-12 is inhibited, by C1q in
a dose-dependent manner. These results are reproducible in
primary M/MØ treated with C1q for 18 h (data not shown),
suggesting that HCV core mimics the function of C1q in inhibiting
M/MØ IL-12 production by regulation of Tim-3 expression.
To determine whether HCV core protein truly alters gC1qR
signaling to disrupt host immunity, we pre-incubated primary M/
MØ with HCV core protein in the presence of anti-gC1qR
antibody or control serum overnight, followed by LPS/R848
stimulation for 18 h, and then examined Tim-3/IL-12 expressions
by flow cytometry. As shown in Fig. 5B, the core-mediated
dysregulation of Tim-3/IL-12 is abrogated by antagonistic anti-
gC1qR, but not by the control antibody, suggesting that HCV
core up-regulates Tim-3 and down-regulates IL-12 expression
through interaction with gC1qR on M/MØ.
Blocking the Tim-3 pathway suppresses PD-1 expression
and enhances IL-12 production in CD14
+ M/MØ
Based on the observations that Tim-3 is over-expressed on M/
MØ that is associated with impaired IL-12 production in chronic
HCV infection, and that HCV (core) contributes to the
induction of Tim-3 and inhibition of IL-12 expression in M/
MØ, we next sought to examine the effect of Tim-3 blockade on
M/MØ IL-12 production. We first employed the HCV-
transfected Huh-7 cell culture system by adding anti-Tim-3 or
control IgG and the purified M/MØ into 48 h-HCV2 or mock-
transfected Huh-7 cells overnight, followed by LPS/R848
stimulation for another 18 h. As shown in Fig. 6A, baseline IL-
12 expression is relatively low in M/MØ incubated with HCV
+
Huh-7 versus HCV
2 Huh-7 cells and stimulated with LPS/
R848/IgG for 18 h, confirming the data above that HCV
exposure inhibits IL-12 expression (Fig. 3D). Nevertheless, IL-12
expression in CD14
+ M/MØ is boosted by blocking Tim-3
signaling in the setting of co-culture with either HCV-transfected
or mock-transfected hepatocytes.
We and others have recently found that PD-1 is involved in
negative regulation of IL-12 production by M/MØ [29–30,33–
34]. Additionally, while Tim-3 and PD-1 could be single
expressed on distinct M/MØ, they are also duly expressed on
certain populations of CD14
+ M/MØ, although the expression
pattern and dynamics of these two negative regulatory molecules
are quite different in innate immune cells (Zhang et al, under
revision in JLB). To delineate any possible relationship between
Tim-3 and PD-1 pathway in human M/MØ as an underlying
mechanism for HCV-mediated IL-12 inhibition, we tested
Figure 2. Tim-3 expression is inversely associated with IL-12 production in M/MØ. Tim-3 expression and IL-12 production in CD14
+ M/MØ
were measured by flow cytometry triple immunostaining in healthy subjects (A) and chronically HCV-infected individuals (B). Representative dot plots
to show the relationship of Tim-3 and IL-12 expressions in CD14
+ M/MØ in un-stimulated and TLR-stimulated are shown above. The correlation
between Tim-3 expression and IL-12 production in M/MØ, evaluated by Pearson Correlation with 2-tailed significance (**,0.01, ***,0.001) denoted
in the upper right corner of each analysis, is shown below.
doi:10.1371/journal.pone.0019664.g002
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expression and restore M/MØ function in chronically HCV-
infected individuals. To this end, PBMC from 6 healthy subjects
and 6 chronic HCV patients were incubated with anti-Tim-3 or
control IgG antibody 48 h, followed by LPS/R848 stimulation
for additional 18 h. Fig. 6B shows representative flow cytometric
dot plots of a healthy and HCV subject measuring PD-1 surface
expression and intracellular IL-12 production in CD14
+ M/MØ,
and Fig. 6C summarizes the data from 6 subjects in each group.
As we expected based on their cell surface expression patterns,
the expression of PD-1 on M/MØ of healthy as well as HCV-
infected subjects is significantly reduced by the blockade of Tim-3
pathway. Furthermore, Tim-3 blocking significantly improves IL-
12 production by CD14
+ M/MØ from both healthy and HCV-
infected subjects when compared with the control IgG. Vice versa,
blockade of the PD-1 pathway by PD-L1 antibody inhibits Tim-3
expression and improves IL-12 expression in M/MØ from HCV
patients (Fig.S2). Collectively, TIM-3 signaling appears to
crosstalk with the PD-1 pathway in regulation of IL-12 expression
by M/MØ during HCV infection.
Tim-3 blockade down-regulates HCV core-mediated
SOCS-1 expression and up-regulates STAT-1
phosphorylation in human M/MØ
We have previously found that HCV core-induced differential
regulation of T and B lymphocyte responses and inhibition of IL-12
expression in M/MØ is mediated by regulation of JAK/STAT
signaling through induction of SOCS-1, which is a negative
immunomodulator upstream of the JAK/STAT pathway [23–
28,33–41]. Sinceblockade of Tim-3 signalingenhances the function
of CD14
+ M/MØ, we next explored the relationship between Tim-
3 and SOCS-1 and whether Tim-3 also negatively modulates TLR-
stimulated M/MØ IL-12 production through the JAK/STAT
pathway. To this end, purified healthy M/MØ were incubated with
anti-Tim-3 or control IgG overnight, followed by HCV core/LPS/
R848 stimulation for 48 h. Cell lysates from these treated cells were
immunoblotted to detect SOCS-1 and phosphorylated STAT-1
protein. b-actin and total STAT-1 were detected to serve as loading
controls. As shown in Fig. 7A, Tim-3 blocking significantly down-
regulates HCV core-induced SOCS-1 gene expression in M/MØ
Figure 3. Tim-3 and IL-12 expression in M/MØ is differentially regulated by hepatocytes expressing HCV. A) Immunofluoresence
staining of HCV core protein in Huh-7 cells 48 h after HCV-JFH-1 (left) or mock (right) transfection. Higher magnificent imaging (640) is inserted at
upper left corner. B) Tim-3 expression on M/MØ co-cultured with HCV-transfected (red line) or mock-transfected (green line) Huh-7 cells without (left)
or with (right) LPS/R848 stimulation. C) Representative Time-course of Tim-3 expression on CD14
+ M/MØ co-cultured with HCV
+ Huh-7 versus HCV
2
Huh-7 cells from two reproducible experiments. D) IL-12 expression in M/MØ co-cultured with HCV
+ Huh-7 versus HCV
2 Huh-7 cells, shown as dot
plot, histogram, and bar figure in multiple experiments.
doi:10.1371/journal.pone.0019664.g003
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decreased SOCS-1 expression, Tim-3 blockade rescues the HCV
core-mediated inhibition of STAT-1 phosphorylation in M/MØ
compared to those treated with control IgG (Fig. 7B). The statistical
analysis of densitometry data from multiple experiments is
significant, as summarized in the bar figures. SOCS-1 and JAK/
STAT signaling pathways thus may be involved in Tim-3-mediated
negative regulation of M/MØ function.
Silencing SOCS-1 gene expression decreases Tim-3
expression and improves IL-12 production in THP-1 cells
To further characterize the relationship between Tim-3 and
SOCS-1 in negative regulation of TLR/core-mediated IL-12
regulation, we silenced SOCS-1 gene expression in THP-1 cells by
transfection of a small interfering RNA (siRNA) specific for
SOCS-1, followed by the treatment of HCV core and LPS/R848
for 48 h and 72 h. Compared with the control siRNA, THP-1
cells transfected with SOCS-1 siRNA exhibit significantly
inhibited expression of SOCS-1 protein at both 48 and 72 h after
transfection [34]. We measured Tim-3 expression and IL-12
production in THP-1 cells after SOCS-1 siRNA transfection and
LPS/R848/core treatment for 48 h and 72 h. As shown in Fig. 8A
and B, compared with control siRNA, Tim-3 expression is
significantly suppressed on SOCS-1 siRNA-transfected THP-1
cells at both time points, but more significantly at 72 h after
transfection. Functionally, transfection of SOCS-1 siRNA im-
Figure 4. Tim-3 and IL-12 expression in primary CD14
+ M/MØ and THP-1 cells are altered by HCV core treatment. A) Healthy PBMC
were treated with b-gal or HCV core and LPS/R848 for 18 h, followed by triple immunostaining and flow cytometric analysis for the expressions of
CD14, TIM-3, and IL-12. PBMC were first gated on monocytic populations, and then further gated on CD14
+ M/MØ (R3). Representative dot plots from
a healthy subject demonstrate the relationship of Tim-3 and IL-12 expression and their response to b-gal or HCV core treatment. Summary data from
8 healthy subjects indicates the effect of HCV core on Tim-3 expression and IL-12 production in primary CD14
+ M/MØ. Mean values are expressed as
percentage of the indicated population. Error bars represent the SD of the mean. The p value (**,0.01; ***,0.001) is denoted above the group of
study subjects. B) Tim-3 expression and IL-12 production in THP-1 cells 72 h after HCV core or b-gal treatment followed by flow cytometric analysis.
The histogram of Tim-3 or IL-12 expression is over-layed upon isotype control and different treatment. The data is reproducible in repeated
experiments. C) Tim-3 (left panel) and IL-12 (right panel) expression in purified CD14
+ M/MØ with no stimulation (blue line), LPS/R848/b-gal treatment
(green line), or LPS/R848/core treatment (red line).
doi:10.1371/journal.pone.0019664.g004
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after transfection of SOCS-1 siRNA versus control siRNA. Similar
to the reactivation of HCV core-mediated inhibition of STAT-1
phosphorylation by Tim-3 blocking (Fig. 7B), silencing SOCS-1
also rescued HCV core-induced STAT-1 dephosphorylation
(Fig. 8C). Collectively, these data suggest that Tim-3 negatively
regulates M/MØ IL-12 expression by crosstalk with other
inhibitory molecules, including PD-1 and SOCS-1, through
limiting STAT-1 phosphorylation.
Discussion
Tim-3 is a newly identified inhibitory molecule that is up-
regulated on dysfunctional T cells during chronic viral infections
[7–10]. The expression and function of Tim-3 on human innate
immune responses during HCV infection, however, remains
unknown. Here, we report that 1) Tim-3 is constitutively expressed
on resting M/MØ, which have little IL-12 expression; upon TLR
stimulation, Tim-3 expression is significantly reduced that
accompanied by increased IL-12 production. 2) Tim-3 expression
on un-stimulated and TLR-stimulated M/MØ in chronically
HCV-infected individuals is significantly higher than healthy
subjects, and this up-regulation can be recapitulated on healthy
M/MØ exposure to HCV-expressing hepatocytes or HCV core
protein. 3) Increased Tim-3 expression consistently correlates with
decreased IL-12 expression by M/MØ, an effect that mimics C1q
function and is reversible by blocking the HCV core/gC1qR
interaction. 4) Most importantly, the TLR-mediated IL-12
expression that occurs primarily in Tim-3 negative M/MØ in
both healthy and HCV-infected patients could be improved by
blocking the Tim-3 pathway. 5) Our findings also shed light on
potential mechanisms by which Tim-3 suppresses M/MØ function
by crosstalk with other negative immumodulators, including PD-1
and SOCS-1, and through altering JAK/STAT signaling.
The TIM gene family consists of eight members (Tim-1 through
Tim-8) on mouse chromosome 11B1.1, and three members (Tim-
Figure 5. HCV core mimics C1q function in regulation of Tim-3 and IL-12 expression through interaction with gC1qR. A) Tim-3 and IL-
12 expression in THP-1 cells treated with C1q (0, 50, and 100 mg/ml) for 48,72 h. Representative histogram over-layed at 72 h is shown above, and
summary data from 3 independent experiments is shown below. B) Regulation of Tim-3 and IL-12 expression in M/MØ by HCV core protein in a
gC1qR-dependent manner. PBMC were pre-incubated with anti-gC1qR or control serum overnight, followed by the stimulation with LPS/R848 in the
presence of HCV core protein for 18 h. Cell surface Tim-3 and intracellular IL-12 expression was detected by flow cytometry. Data are reproducible in
6 independent experiments.
doi:10.1371/journal.pone.0019664.g005
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that has been shown linked with asthma, allergy, and other
autoimmune disorders [43–44]. All TIM-family proteins share a
common architecture in which the extracellular region possesses a
membrane-distal IgV domain and a membrane-proximal mucin
domain [45–47]. Tim-3 plays an important role in the immune
regulation of autoimmune diseases as well as viral infections and
has been described as a bi-modal immune regulator in different
disease scenarios [48]. In autoimmunity, loss of Tim-3 leads to
excessive expansion of auto-reactive T cells [5,49]. In chronic
HCV, HIV, and HSV infections, in contrast, sustained Tim-3
expression on CD4
+ and CD8
+ T cells leads to T cell exhaustion
[7–10,50]. Gal-9 was identified as a ligand for Tim-3, and
engagement of the Tim-3 IgV domain by gal-9 is important for
termination of T cell responses and induction of T cell apoptosis as
well as differentiation of regulatory T cells (Treg) expressing FoxP3
[11,51,52].
In addition to T lymphocytes, we now know that Tim-3 is also
expressed by other immune cells, including natural killer cells
(NK), dendritic cells (DC), monocytes and mast cells, and appears
Figure 6. Tim-3 blockade significantly improves IL-12 production and reduces PD-1 expression on CD14
+ M/MØ. A) Purified M/MØ was
incubated with Huh-7 cells in a ratio of 10:1 at 48 h after HCV or mock transfection. Anti-Tim-3 or control IgG was added into the co-culture system at
the same time and incubated overnight, followed by stimulation with LPS/R848 for another 18 h. IL-12 expression in CD14
+ M/MØ was detected by
flow cytometry. B) Representative flow cytometric dot plots from one healthy subject and one HCV-infected individual showing the effect of Tim-3
blocking on PD-1 and IL-12 expressions in CD14
+ M/MØ. Gating strategy for identifying CD14
+ M/MØ subsets is the same as in Fig. 4A. C) PBMC from
healthy subjects (n=6) and chronically HCV-infected individuals (n=6) were pre-incubated with anti-Tim-3 or control IgG antibodies 48 h, followed
by stimulation with LPS/R848 for 18 h. PD-1 and IL-12 expressions were detected by flow cytometry. The percentages of PD-1
+ CD14
+ M/MØ or IL-12
+
CD14
+ M/MØ of healthy subjects as well as chronically HCV-infected individuals are shown. The p value (*,0.05, **,0.01) was denoted above the
group of study subjects.
doi:10.1371/journal.pone.0019664.g006
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previously thought [14,53–55]. In the present study, Tim-3 was
found constitutively expressed on naı ¨ve M/MØ, functioning as a
cap or brake to block pro-inflammatory cytokine IL-12 produc-
tion. Tim-3 expression was significantly reduced, accompanying
with enhanced IL-12 production following TLR stimulation. This
is quite different from Tim-3 expression pattern on T cells, which
show a very low level on naı ¨ve CD4
+ and CD8
+ T lymphocytes,
increase level along with T cell activation (CD69 expression) by
anti-CD3/CD28 stimulation (Fig.S3), although Tim-3 plays
inhibitory role in both innate and adaptive immune cells
(functioning as a cap in M/MØ, while working in a feedback
mechanism in T cells). Notably, our results demonstrate an
expression pattern and functionality of Tim-3 that differs
somewhat from the albeit limited human studies presented by
Anderson AC et al, reporting that Tim-3 is primarily expressed on
DCs and synergizes TLR to promote inflammation and serving
opposite roles in the innate and adaptive immune systems [14].
This disparity is possibly due to the differences in the stimulation
methods, the cell differential status, and the time-points chosen to
evaluate the Tim-3 expression on human M/MØ in different
laboratory. Our studies of Tim-3 expressions on M/MØ from both
healthy and HCV-infected individuals show the same dynamic
pattern suggest that it is not due to the difference of disease
models. Our present data demonstrate that blockade of Tim-3
signaling significantly boosts LPS-mediated IL-12 production,
which provides a firm demonstration that Tim-3 functions as a
brake rather than a promoter in innate immune responses. This
Tim-3 negative regulatory effect on innate immunity has also been
reported by other investigators [12–13]. Notably, blocking Tim-3
in the absence of LPS stimulation does not alter IL-12 expression
(Zhang et al, under review in JLB). This brake is at least transiently
released following TLR activation, and its release without
providing acceleration (TLR stimulation) has no consequence;
whereas releasing Tim-3 and providing the necessary stimulation
results in enhanced M/MØ function. We thus propose Tim-3 may
indeed be important in permitting inflammation per se but does so
by a decrease in its expression that permits TLR signaling to drive
inflammatory responses.
Our observation that M/MØ from chronically HCV-infected
subjects exhibit higher levels of Tim-3 expression and lower levels
of IL-12 expression than healthy subjects implies a direct role for
the HCV in the up-regulation of Tim-3 expression and functional
impairment of M/MØ. Notably, we simultaneously analyzed the
expressions of IL-12, IL-6, IL-10, and TNF-a in CD14
+ M/MØ
from multiple HCV-infected individuals and healthy subjects by
flow cytometry and found that IL-12 is selectively suppressed
during chronic HCV infection in M/MØ in response to ex vivo
LPS/R848 stimulation [33]. Additionally, to determine whether
M/MØ from HCV-infected individuals fail to respond to these
Figure 7. Tim-3 blockade down-regulates HCV core-mediated SOCS-1 expression and up-regulates STAT-1 phosphorylation in
primary M/MØ. Purified M/MØ was treated with Tim-3 antibody or control IgG overnight, followed by HCV core and LPS/R848 stimulation for 48 h.
A) SOCS-1 or B) phospho-STAT-1 was detected by immunoblotting. Representative Western blot imaging is shown in the left, and summary of
densitometry data with statistical analysis (*p,0.05, **p,0.01) from three independent experiments are shown on the right.
doi:10.1371/journal.pone.0019664.g007
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pathogens, we also analyzed the expression of TLR4 and TLR7
in M/MØ from HCV-infected versus healthy subjects. To our
surprise, TLR4 was found to be expressed high, but not low, on
M/MØ from HCV-infected versus uninfected subjects, while
TLR7 was highly detected, with no difference, in both HCV-
infected and healthy subjects, signaling that the problem may lie at
the downstream signaling pathways [33]. Multiple HCV antigens
have been noted to be immunomodulatory and may be
contributing to these findings, among which HCV core protein
has a distinct immunosuppressive capacity and has been shown by
us to inhibit IL-12 production in human M/MØ by yet unclear
mechanisms [34,40]. In the present study, we demonstrate that
Tim-3 expression can be up-regulated by HCV core protein,
accompanied by a down-regulation of IL-12 expression, in both
primary healthy CD14
+ M/MØ and THP-1 cells. IL-12 is mainly
produced by Tim-3 negative M/MØ, suggesting that high Tim-3
expression may identify a subset of functionally naı ¨ve or impaired
M/MØ with limited IL-12 expression. This complements and
integrates previous studies that have identified an important role
for HCV core in immunoregulation [37,56], and Tim-3 seems
likely to be one of many molecules that mediate HCV core
functionality. Certainly other HCV antigens may contribute to this
dysregulation as well, and this deserves further investigation.
We have previously demonstrated that HCV core differentially
regulates T and B lymphocyte functions and inhibits IL-12
production through interaction with gC1qR expressed on immune
cells [23–38,33–41]. gC1qR is a multifunctional protein that
interacts with multiple ligands, including many derived from
pathogenic organisms [42], such as HIV-Tat and Rev, EBV
EBNA-1, HSV-ORF P, adenovirus core protein-V, L. monocyto-
genes-InlB, and S. aureus-protein A. These pilot studies suggest that
microorganisms may capitalize gC1qR as a shared mechanism of
immune evasion, and thus the role of gC1qR in the pathogenesis
of these pathogens has been the subject of further investigation. In
this study, we demonstrate that C1q, the natural ligand of gC1qR,
can dose-dependent up-regulate Tim-3 and inhibit IL-12 expres-
sion in a manner similar to HCV core protein, which has been
shown to bind gC1qR as one of its mechanisms of immunomod-
ulation [35,39]. Importantly, blocking gC1qR abrogates HCV
core-induced Tim-3/IL-12 dysregulation. To our knowledge, this
is the first demonstration that HCV core protein mimics the
function of complement C1q, at least in part, in inhibition of IL-12
expression by up-regulation of Tim-3 through interaction with
gC1qR.
The mechanisms of HCV-mediated Tim-3 up-regulation
probably involve in the following two aspects: i) HCV may
increase Tim-3 gene transcription or translation; ii) HCV may
decrease or slowdown Tim-3 protein degradation. HCV inhibits
monocyte activation might be a cause for Tim-3 elevation detected
in both HCV-infected patients or co-cultured with HCV-
expressing hepatocytes, rather than HCV-induced Tim-3 causes
Figure 8. SOCS-1 silencing regulates HCV core-mediated Tim-3 expression, IL-12 production, and STAT-1 phosphorylation in THP-1
Cells. A) and B) THP-1 cells were transfected with SOCS-1 siRNA or control siRNA, followed by HCV core and LPS/R848 stimulation for another 48 and
72 h, then subjected for the expression of Tim-3 and IL-12 analysis by flow cytometry. C) The same cells were also subject to Western blot for
detection of STAT-1 phosphorylation. The figures show one representative blot and summary densitometry data of 3 repeated experiments.
doi:10.1371/journal.pone.0019664.g008
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improved IL-12 production, suggesting the causing effect of Tim-3
in control of IL-12 expression. Notably, improvement of cell
function by blocking Tim-3 pathway is observed in the absence of
HCV core, and this phenomenon has also been demonstrated by
us for other inhibitory molecules such as PD-1 and SOCS-1, in
M/MØ as well as in T cells [26,34]. These results indicate that
Tim-3, PD-1, and SOCS-1 inhibitory molecules are pre-existing
and function in a network in cell negative regulation. It seems
plausible that HCV, in order to survival or persistence in vivo, may
exploit this pre-existing cell mechanism to impair host immunity,
i.e., HCV (core) is taking advantage of the intrinsic mechanism by
magnification of these negative signaling molecules, breaking the
balance to positive co-stimulatory molecules, for its own benefit of
survival in the host, thus leading to viral persistence.
In this study, blockade of Tim-3 pathway was found to enhance
IL-12 production in M/MØ of healthy and HCV-infected
subjects, suggesting that the Tim-3 pathway plays a crucial role
in suppressing M/MØ functions. Additionally, IL-12 expression is
affected not only by Tim-3, but by other negative immunomod-
ulators, such as PD-1 and SOCS-1 [29–34]. As we show in this
study, blockade of the Tim-3 pathway suppresses PD-1 expression
as well as HCV core-mediated PD-1/SOCS-1 expression and
improves STAT-1 phosphorylation in primary M/MØ, while
blocking PD-1 signaling or silencing SOCS-1 gene expression also
decreases Tim-3 expression and enhances IL-12 secretion and
STAT-1 phosphorylation. This implies potential crosslink amongst
these molecules in negatively regulating innate immunity during
chronic HCV infection. These observations support a plausible
notion that Tim-3, PD-1 and SOCS-1, while seemingly regulating
cell signaling at different levels, are actually associated or linked in
an inhibitory circuit or form a cluster to prevent ubiquitin-
degradation, and exert an integrated role in suppressing cell signal
transduction. Thus, blockade the signaling of one molecule leads
to a change (either decreased degradation or increased transcrip-
tion/translation) in the others within cells to improve the IL-12
expression, which has been consistently demonstrated in this and
our other studies.
Studies on the pathogenesis of HCV have been significantly
advanced since the establishment of an in vitro cell culture model
using Huh-7 hepatocytes-transfected with HCV-JFH-1 strain [19–
20]. With the aid of Drs T. Wakita and T.J. Liang [19–20], we
have successfully established an HCV-transfected Huh-7 model
co-cultured with purified M/MØ, a model which provides us with
a unique cell culture system to study host cell interactions that can
more closely mimic the in vivo setting. By employing this novel
system in our present study, we have demonstrated that Tim-3 is
up-regulated by HCV to inhibit IL-12 expression. Based on this
and our previous studies, we propose a pathogenesis model (Fig. 9)
in that HCV core protein secreted from HCV-infected hepato-
cytes binds to gC1qR displayed on macrophages, up-regulating
Tim-3, PD-1, and SOCS-1 negative immunomodulators that can
crosstalk each other and coordinately inhibit cell signaling
transduction, resulting in an impaired innate immune response
with a cytokine environment (deficient IL-12/TNFa/IFN-c) that
is permissive for suppression of adaptive immune responses in the
liver so as to facilitate the establishment of persistent infection.
Whether other structural or non-structural proteins in additional
to HCV core protein contribute to Tim-3/IL-12 dysregulation is
under investigation in our laboratory using this model system.
In conclusion, this study presents a novel and crucial role for
Tim-3 as a negative regulator of M/MØ function in innate
immune responses to HCV infection. The identification of Tim-3
expression and function in innate immune cells in a human disease
model provides a new perspective to understanding the roles of
this negative molecule as a potential target for immune therapy of
chronic HCV infection.
Materials and Methods
Subjects
The study subjects composed of two populations, with the first
group consisting of 21 chronically HCV-infected subjects. HCV
genotype and viral load were performed by Lexington VAMC and
all subjects were virologically and serologically positive for HCV,
prior to the treatment with IFN/RBV (Table 1). The second
group includes 12 healthy subjects who are negative for HBV,
HCV, and HIV infections. Written informed consent was
obtained from all participants, and the study was approved by
an institutional review board at East Tennessee State University
and James H. Quillen VA Medical Center (Johnson City, TN).
Cell isolation and culture
Human peripheral blood mononuclear cells (PBMC) were
isolated from whole blood using Ficoll density gradient centrifu-
gation (Atlanta biological, Lawrenceville, GA). Human primary
Figure 9. A Model for the HCV core/gC1qR-induced negative signaling (Tim-3/PD-1/SOCS-1) molecules in regulation of IL-12 and
Th1/Tc1 responses during HCV infection. We have previously shown that HCV core/gC1qR interaction up-regulates PD-1 and SOCS-1 negative
signaling molecules, leading to suppression of TLR-mediated IL-12 production. In this study, we further demonstrated that the Tim-3 inhibitory
pathway is involved in the HCV core/gC1qR-induced inhibition of IL-12 expression by M/MF during HCV infection. Specifically, we found that Tim-3
can be up-regulated by HCV core/gC1qR interaction, which in turn, inhibits TLR-mediated IL-12 production. We also found that Tim-3 can crosstalk
with other inhibitory molecules such as PD-1 and SOCS-1 to coordinately inhibit TLR-mediated IL-12 signaling pathways during HCV infection. We
conclude that HCV-mediated innate immune dysregulation (impaired M/MF IL-12 production) may ultimately lead to adaptive Th1/Tc1 dysfunction,
and thus, HCV persistence.
doi:10.1371/journal.pone.0019664.g009
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gradients (GE Heathcare, Piscataway, NJ). PBMC and M/MØ
were viably frozen in 30% fetal bovine serum (Life Technologies,
Gaithersburg, MD), 10% dimethyl sulfoxide (DMSO) and 60%
RPMI 1640 medium (Mediatech, Inc, Manassas, VA) in liquid
nitrogen. For subsequent analysis, the frozen PBMC and M/MØ
were thawed, washed and cultured with RPMI 1640, containing
10% fetal bovine serum (FBS, Life Technologies, Gaithersburg,
MD), 100 mg/ml penicillin-streptomycin (Thermo Scientific,
Logan, Utah), and 2 mM L-glutamine (Thermo Scientific, Logan,
Utah). A human monocytic cell line, THP-1 cells, was obtained
from ATCC (American Type Culture Collection, Manassas, VA)
and cultured in RPMI 1640 (ATCC, Manassas, VA), containing
10% FBS, 100 mg/ml penicillin-streptomycin, and 0.05 mM b-
mercaptoethanol (Sigma-Aldrich, St. Louis, MO) at 37uC with 5%
CO2 atmosphere.
Flow cytometry
PBMC or THP-1 cells were stimulated by 5 mg/ml of LPS and
5 mg/ml of R848 (InvivoGen, San Diego, CA - that can
synergistically activate primary M/MØ to produce IL-12) in the
presence or absence of 2 mg/ml of HCV core protein (ViroGen,
Watertown, MA) or 50 and 100 mg/ml C1q (Quidel Corporation,
San Diego, CA) for 18,72 h depending on the experimental
requirements as described in the result, followed by Brefeldin A
(BioLegend, San Diego, CA) 6 h prior to harvest the cells for
inhibiting cytokine secretion. Specific antibody direct conjugates
for cell surface staining was carried out using Tim-3 (R&D,
Minneapolis, MN), or PD-1 (BD Biosciences, San Jose, CA), and
CD14 (Miltenyi Biotec Inc, Auburn CA), followed by intracellular
staining for IL-12 (Miltenyi Biotec Inc). The intracellular cytokine
staining was carried out using an Inside Stain kit (Miltenyi Biotec
Inc). Isotype-matched control antibodies (BD Biosciences, San
Jose, CA) were used to determine background levels of staining.
The cells were analyzed on a FACSCalibur flow cytometry (BD,
Franklin Lakes, NJ) and CELLQuest software.
Huh-7 hepatocytes transfection by HCV-JFH-1 and co-
culture with primary M/MØ
HCV JFH-1 (kindly provided by Dr. T. Wakita, Department of
Virology II, NIH of Japan through a MTA) was transfected into
MAX EfficiencyH DH5a
TM Competent Cells, replicated, and
purified by a plasmid miniprep kit (Invitrogen corporation,
Carlsbad, CA). The purified DNA was linearized with XbaI
(Promega Corporation. Madison, WI) and Mung Bean Nuclease
(New England BiolabsIpswich, MA), and further purified with
OriGene powerprepTM Express PCR purification kit (OriGene
Technologies, Inc. Rockville, MD). Reverse transcription of the
DNA into mRNA was carried out by a MEGA scriptH T7 Kit and
purified by MEGAclearTM kit (Ambion,Inc Austin, TX) per
manufactruer’s instructions. 5610
5 Huh-7 hepatocytes (kindly
provided by Dr. T.J.Liang, liver section, NIH/NIDDK) were
transfected at 60,70% confluent in a 6-well plate with 5 mg HCV
mRNA using DMRIE-C reagents per company’s protocol
(invitrogen corporation, Carlsbad, CA). HCV antigen expression
was examined at 24, 48, and 72 h after transfection by
immunoflourescence using HCV core and NS5 antibodies
(ViroGen, Watertown MA). HCV replication was also demon-
strated by RT-PCR amplify HCV core mRNA from the
supernatant of JFH-1-transfected Huh-7 culture, and by inocula-
tion of uninfected Huh-7 cells with the 48 h supernatant of JFH-1-
transfected Huh-7 culture. Mock-transfection (without HCV
Table 1. Characteristics of subjects included in the study.
Subject Age Race Gender ALT/AST Genotype Viral Load (IU/ml)
1 59 Caucasian M 78/61 1a 2,569,032
2 51 African-American M 65/79 1a 8,476,003
3 52 Caucasian M 73/55 1a 489,591
4 59 Caucasian M 30/24 4b 887,509
5 48 Caucasian M 65/55 1a 4,547,924
6 49 Caucasian M 103/141 1a 2,298,550
7 63 Caucasian M 99/69 3a 3,260,000
8 51 Caucasian M 109/92 1a 3,653
9 35 Caucasian M 34/43 2b 40,100,000
10 53 Caucasian M 76/89 1a 1,890,00
11 50 Caucasian M 163/137 3a 11,641,000
12 35 Caucasian M 121/109 3a 4,190,619
13 51 Caucasian M 99/103 1a 4,790,000
14 48 African-American M 133/112 1a 422,263
15 53 Caucasian M 73/59 1a 173,294
16 56 Caucasian M 178/146 3a 1,360,000
17 52 Caucasian M 109/135 3a 30,900,000
18 26 Caucasian M 83/57 1a 1, 106,553
19 55 Caucasian M 65/77 1a 69,300
20 49 African-American M 112/134 1a 20,000 ,000
21 56 Caucasian M 89/57 1a 5,206 ,273
doi:10.1371/journal.pone.0019664.t001
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control. For the co-culture experiment, purified M/MØ were
incubated with hepatocytes in a ratio of 10:1 at 48 h after HCV/
mock-transfection, and stimulated with or without LPS/R848 for
another 6,48 h. The expression of Tim-3 and IL-12 in M/MØ
was examined by flow cytometry.
Tim-3, PD-1, or gC1qR blockade
Healthy and/or HCV patients’ PBMC or purified M/MØ were
incubated with 10 mg/ml anti-TIM3 (R&D Systems) or 5 mg/ml
anti-PDL-1 (eBioscience) or 1:10 diluted antagonistic gC1qR
antibody (generously provided by Dr. Y.S. Hahn, University of
Virginia) or control IgG overnight, followed by stimulation with
2 mg/ml of HCV core protein (ViroGen, Watertown, MA), 5 mg/
ml of LPS and 5 mg/ml of R848 for 24,72 h, then subjected for
flow cytometric detection of PD-1 or Tim-3 and IL12 expressions.
Tim-3-blocked, purified monocytes treated as above were also
lysed for Western blot detection of SOCS-1 (Millipore, Temecula,
CA) and phospho-STAT-1 (Tyr 701, Cell Signaling Technology,
Inc. Danvers, MA). b-actin and total STAT-1 serve as loading
control.
siRNA silencing of SOCS-1
3610
5 THP-1 cells were incubated with 60 pmols SOCS-1
siRNA duplex or control siRNA in 200 ml siRNA Transfection
Medium in a 6-well plate per manufacturer’s instruction (Santa
Cruz Biotechnology, Santa Cruze, CA). Following 6 h of
incubation at 37uC, normal growth medium containing 26
concentrations of normal serum and antibiotics was added. The
transfected cells were stimulated with 5 mg/ml LPS and R848 in
the presence of 2 mg/ml HCV core for 48,72 hrs, followed by
detection of SOCS-1/Tim-3/STAT-1/IL-12 as described above.
Western blot
The purified M/MØ or THP-1 cells were treated as described in
the Tim-3 blocking or SOCS-1 silencing experiments and the
expression of SOCS-1 or phospho-STAT-1 were measured by
Western blot. The primary M/MØ or THP-1 cells were lysed in
16RIPA lysis buffer (Boston BioProducts Inc, Ashland, MA)
supplied with protease inhibitors/phosphorylase inhibitors
(Thermo Scientific, Rockford, IL) and EDTA on ice. Cell lysates
were centrifuged for 15 min at 4uC and the protein concentrations
were measured. Protein samples were thereafter combined with
46 Laemmli sample buffer (Boston BioProducts, Ashland, MA),
denatured, and separated by SDS-PAGE. Following transfer to an
Amersham Hybond-P membrane (GE Heathcare, Piscataway,
NJ), the membrane was blocked and probed with anti-SOCS-1
(Millipore, Temecula, CA) or actin (Santa Cruz Biotechnology,
Santa Cruze, CA) antibody at 4uC overnight. For detection of
phospho-STAT-1 and total STAT-1, the membrane was probed
with anti-Phospho-STAT-1 (Tyr701) or total STAT-1 antibody
(Cell Signaling Technology, Inc, Danvers, MA). Finally, the
membrane was incubated with a horseradish peroxidase-conju-
gated secondary antibody (Millipore, Temecula, CA) and
developed by Amersham
TM ECL Plus Western Blotting Detection
Reagents (GE Healthcare Biosciences, Pittsburgh, PA) on Kodak
X-OMAT-LS X-ray film (Sigma-Aldrich, St. Louis, MO).
Statistical analysis
Study results are summarized for each group and results are
expressed as the mean 6 standard deviation (SD). Comparison
between two groups is performed using multiple comparison
testing—least significant difference or Turkey’s procedure de-
pending on the ANOVA F-test by SPSS 18 software. Barforonni
correction is applied for those samples with multiple tests. Pair wise
t-test is used to compare the significance of PD-1 and IL-12
expressions in Tim-3 blocking experiment. Correlations between
TIM-3 expression and IL-12 production were analyzed by a
Pearson Correlation program. Values of p,0.05 (*), p,0.01(**),
and p,0.001 (***) were considered significant or very significant.
Supporting Information
Figure S1 Conformation of HCV replication in hepato-
cyte culture system. A) Immunofluorescience staining of HCV
NS5 protein in HCV-transfected Huh-7 versus mock-transfected
Huh-7 cells at 48 h. B) RT-PCR of HCV core mRNA in the
supernantant of HCV-transfected Huh-7 versus mock-transfected
Huh-7 cells at 36 h. C) Immunofluorescience staining of HCV
NS5 protein in Huh-7 cells infected by the supernatant of HCV-
transfected Huh-7 cells at 48 h.
(TIF)
Figure S2 Blockade of PD-1 signaling by anti-PDL-1
antibody decreases Tim-3 expression and improves IL-
12 production by CD14
+ M/MØ.
(TIF)
Figure S3 Tim-3 and CD69 expressions on naı ¨ve and
activated CD4
+ and CD8
+ T lymphocytes. PBMC from 3
healthy subjects were stimulated with or without anti-CD3/CD28
for 24 h followed by flow cytometric analysis of Tim-3 and CD69
expressions on CD4
+ and CD8
+ T cells. Summary data of
percentages of Tim-3
+ or CD69
+ cells in naı ¨ve versus activated
CD8
+ (A) or CD4
+ (B) lymphocytes are shown, and the p value
(**,0.01; ***,0.001) is denoted above the group of study
subjects.
(TIF)
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